Experiment 490247

Details

PropertyValue
Pharmacology
Administration routeIV INFUSION
OrganismEmpty organism
CitationGOSS,PE: BAPTISTE,J: FERNANDES,B: BAKER,M: DENNIS,JW:. (1994). A PHASE I STUDY OF SWAINSONINE IN PATIENTS WITH ADVANCED MALIGNANCIES.. 54(6)
Amount utilized
Compound isolated
DiseaseIN THIS PHASE I STUDY 19 PATIENTS WITH BOTH SOLID TUMOR AND HEMATOLOGICAL MALIGNANCIES WERE TREATED WITH DOSES OF 50-550 MCG/KG/DAY. SIDE EFFECTS INCLUSED EDEMA, LIVER DYSFUNCTION, ELEVATED SERUM AMYLASE AND DECREASED SERUM RETINOL. DOSE LIMITING TOXICITY WAS HEPATOTOXICITY. CLEARANCE AND SERUM HALF-LIFE AND 0.5 DAY RESPECTIVELY. ONE PATIENT WITH HEAD AND NECK CANCER SHOWED >50% SHRINKAGE OF TUMOR MASS.
Dose amountVAR
Number1
Qualitative resultEQUIVOCAL
AnimalHUMAN ADULT
Dose expressionDOSE